Taros Chemicals, Welab ink partnership deal to aid client R&D
20 Apr 2023
Preview
Source: FierceBiotech
Welab’s contribution is its R&D platform.
Taros Chemicals, a German small molecule CRO, inked a partnership deal with Spain’s Welab in an effort to broaden their scope of R&D offerings to clients.
Under the agreement, pharma and biotech companies will get access to Taros’ synthetic and medicinal chemistry expertise that covers "hit identification, hit to lead and lead optimization" as well as drug design and molecular modeling services.
Welab’s contribution is its R&D platform providing in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics, and toxicology services, the two companies said in an April 12 press release. Financial terms of the deal weren’t disclosed.
Combined, the two offer a library of more than 115,000 druglike compounds and address specific modalities like peptides and oligonucleotides chemistry.
“Many of our customers have kept asking our drug discovery experts for genuine native integrated biology services,” Taros CEO Dimitrios Tzalis said in the release. “Establishing this partnership with our Spanish colleagues will now close this gap and provide our clients with an end-to-end portfolio along the execution of their pre-clinical development programs.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.